Effect Of Semaglutide In Coronary Atheroma Plaque

NCT05071417 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can change the amount of plaque buildup in the heart arteries of adults with coronary artery disease.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 120 people Planned (estimated).

Who can join Ages 35–65 · all sexes

Timeline Started 2021-11 · est. completion 2025-12

What this study is testing ClinicalTrials.gov NCT05071417 ↗

Description as written by the study sponsor.

The main objective of this trial is to evaluate the effect of Semaglutide on the burden of coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic subjects with T2D in optimized and stable treatment with Semaglutide.

Treatments tested

Semaglutide Drug

Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly

Main thing measured	Plaque burden modification assessed by coronary CT and plaque quantification
Sponsor	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Conditions studied	Atheroscleroses, Coronary
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05071417 ↗